梅州子宫附件炎怎么引起的(梅州女人上环费用) (今日更新中)

BEIJING, Jan. 1 (Xinhua) -- State Grid Corporation of China (SGCC), the country's largest power supplier, said Sunday it has put to trial operation a cross-border electricity transmission project in northeastern Heilongjiang province to supply Chinese with Russia's electric power exports.The electric power SGCC purchased from Russia began reaching Chinese customers late Saturday night after the completion of the direct-current back-to-back networking substation, or called "the trans-Amur project" by Russians, SGCC said in a statement on its website.The trial operation will last 168 hours, SGCC said in the statement.With a transmission capacity of 750 mega-watts, the electricity transmission project is China's biggest cross-border power line, according to SGCC."The implementation of the project will gain experience for the expansion of Sino-Russian energy cooperation and help promote the economic development for both countries," SGCC said.The project is also part of the Sino-Russian energy and trade cooperation.Russian Deputy Energy Minister Andrei Shishkin said in June 2011 that the transmission project would increase Russia's power supply to five or six billion kilowatt hours of electricity to China and Russia intended to increase its electricity supply to China in the coming years.Russian companies plan export 60 billion kwh of electricity to China by 2020. Power plants will be built along its border with China to reduce power transmission losses and reduce transportation costs.Also on Sunday, an oil pipeline linking Russia's far east and northeast China witnessed its one year anniversary of operation, as operators announced an accumulated 15 million tonnes of oil had been transported into China in 2011.

UNITED NATIONS, Nov. 21 (Xinhua) -- Dramatic progress in science, political leadership, and results indicate that 2011 was a "game changing" year for the international AIDS response, and much progress has been made in 2011 to check AIDS-related deaths since 1997, the peak of the epidemic, a new report released by the Joint United Nations Program on HIV/AIDS (UNAIDS) said on Monday."The Report on the Global AIDS Epidemic 2011" found that new infections were reduced by 21 percent since 1997, and deaths from AIDS-related illnesses decreased by 21 percent since 2005, according to the report.Furthermore, 47 percent (6.6 million) of the estimated 14.2 million people eligible for antiretroviral therapy treatment in low- and middle-income countries were accessing treatment, in increase of 1.35 million people since 2009.The report also found early signs that HIV treatment is having an impact on reducing the number of new HIV infections. As treatment reduces the viral load of a person living HIV to almost undetectable levels, it also reduces the risk of transmitting the virus to an uninfected partner, according to the report. Studies also show that treatment can be up to 96 percent effective in preventing HIV transmission among couples.Eleven countries, including many Sub-Saharan African countries, reached "close to universal access" for AIDS treatment, which is determined to be 80 percent access, in 2011.Botswana made the most dramatic progress in scaling up access to treatment, the report said. While sexual patterns remained relatively stable in the country since 2000, access to treatment increased from less than 5 percent in 2000 to more than 80 percent in 2011.Despite progress, however, the report does note that 2011 marks an unprecedented high the number of people infected with HIV worldwide.Globally, an estimated 34 million people are currently living with the infection. Approximately 2.7 million got infected with the virus in 2010, and as many as 1.8 million people died of AIDS- related illnesses in 2010.Yet the report also notes estimates that as many as 2.5 million deaths are estimated to have been averted in low- and middle- income countries due to increased access to HIV treatment since 1995."Now is not the time to reduce our efforts despite some good news on reducing new infections. Infections are decreasing, but not rapidly enough," said Kim Nichols, executive director of African Services Committee, on Monday at a press conference."There are fewer AIDS deaths, but with the number of infections increasing, prevention has to be the mainstay of our response," Nichols said.Indeed, the UNAIDS report calls for a new framework for investments which are focused on "high-impact, evidence-based, high-value strategies," according to a press release from the UNAIDS website.The framework, which aims to achieve universal access to treatment and prevention centers by 2015, requires a 22-24 billion US dollar funding increase by 2015.Given the withering state of the global economy -- donor funding for the AIDS response has dropped from 7.6 billion in 2009 to 6.9 billion in 2010 -- raising that kind of money may be a long shot. Regardless, UNAIDS'new investment plan calls for smarter uses of less money.According to the report, the framework will focus on high-risk populations like sex workers, men who have sex with men, and people who inject drugs and prevent infections among children, as well as invest in behavior change programs, condom promotion, and treatment, care and support for people living with HIV."The world faces a clear choice: maintain current efforts and make incremental progress, or invest smartly and achieve rapid success in the AIDS response," says the UNAIDS report.

WASHINGTON, Dec. 21 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Wednesday approved Isentress for the treatment of HIV-1 infection for children and adolescents.The drug is part of a class of medications called HIV integrase strand transfer inhibitors that works by slowing the spread of HIV in the body. It was first approved for use in adult patients in October 2007, under FDA's accelerated approval program."Many young children and adolescents are living with HIV and this approval provides an important additional option for their treatment," said Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.Isentress is a pill that can be taken twice daily, with or without food. The pill is also available in a chewable form. As the two tablet formulations are not interchangeable, the chewable form is only approved for use in children ages 2 to 11.A single, multi-center clinical trial of 96 children and adolescents aged 2-18 years with HIV-1 infection evaluated the safety and effectiveness of Isentress. These patients previously received treatment for HIV-1 infection. After 24 weeks of treatment with Isentress, 53 percent of these patients had an undetectable amount of HIV in their blood.According to the FDA, the most commonly reported severe, treatment-related side effects in patients taking Isentress include trouble sleeping and headache. The frequency of these side effects is similar for children and adults. One pediatric patient reported severe treatment-related insomnia, while another pediatric patient experienced a drug-related skin rash.

SAN FRANCISCO, Dec. 29 (Xinhua) -- The United States Patent and Trademark Office on Thursday published a patent application from Apple related to face and presence detection for iOS devices, which is expected to be one of the next chapters for mobile security.According to AppleInsider, a news and rumor website focusing on Apple, the patent is entitled "low threshold face recognition" which is a low-computation solution for quickly and accurately recognizing a user on iPhone, iPad, iPod Touch and MacBook.Patently Apple, a blog focusing on Apple's latest intellectual properties, said that iOS devices would acknowledge the presence of the potential user by turning on the display and then trigger a subsequent process for recognizing the potential user's face.Currently, most face recognition systems tend to be robust ones working in various lighting conditions, orientations, scale and etc., which will require computing resources and drain battery life. There are also security-type face recognition systems working under controlled lighting conditions which could be ineffective due to factors like proximity of the user to the camera.Google's latest Android 4.0 operating system, codenamed Ice Cream Sandwich, already features face detection. But it is reported that the feature doesn't always work and can be bypassed by using a photograph of the phone's owner.Apple's solution would reduce the impact of lighting conditions and biometric distortions on an image, said AppleInsider, citing the filing. Apple said it would rely on a "high information portion" of a human face, such as eyes, mouth or the tip of a user 's nose.The "likely presence" of a human face in front of the camera would be captured through an "orange-distance filter" which would also be used to detect the potential user's skin tone and measure the distance of their face from the camera.Meanwhile, iOS devices could also be set to recognize faces of multiple users, presenting each user with a personalized configuration.According to AppleInsider, the patent application was first filed by Apple in June, 2009.Analysts said that the proposed technology could be Apple's next big innovation as it has record of redesign and give its unique appeal to products that have not caught on with the general public.

BEIJING, Nov. 9 (Xinhuanet) -- Routine bowel screening can cut deaths from bowel cancer by 27 percent, a latest Scottish study finds.The result was presented at the National Cancer Research Institute's (NCRI) conference in Liverpool. Funded by the Scottish government's health department, the study involved over 370,000 people aged 50 to 69 from Scotland. Every participant was given a FOBt (faecal occult blood test) kit-- which was used to collect their stool samples-- every two years between 2000 and 2007. The samples were sent to a laboratory for hidden traces of blood test.Under the monitor of the researchers, the participants saw a 27 percent fewer bowel cancer deaths than a similar number of people from Scotland uninvolved in the trial."For the first time, we can see the effects of an FOBt-based colorectal cancer screening program in the real world of the NHS," cheered author Robert Steele from the Bowel Screening Research Centre in Dundee.According to a BBC report, when bowel cancer is detected at the earliest stage, 90% of patients survive for at least five years. After the disease has spread, the survival rate is just 6%.

来源：资阳报